Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:33:10.135Z.
Calculation as of: 2026-10-06T20:33:10.135Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8cbf2c4bedb1eff0bddc45c0acac52f2eee77af7ab0e1536e55dbd1c791948ce
PE RATIO
N/A
Market Cap
$3.38B
PE Ratio
8.89
TTM Avg
12.92
3Y Avg
23.68
5Y Avg
23.68
Market Cap
$2.99B
PE Ratio
114.72
TTM Avg
121.55
3Y Avg
121.55
5Y Avg
121.55
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.19B | N/A | N/A | N/A | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A | 7.81 | 7.81 | 7.81 |
| CareDx, Inc (CDNA)vs › | $3.30B | 30.80 | 18.61 | 17.43 | 17.43 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | N/A | 239.54 | 239.54 | 239.54 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | N/A | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 8.89 | 12.92 | 23.68 | 23.68 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 114.72 | 121.55 | 121.55 | 121.55 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$74.11
Forward EPS (Est.)
$-2.08
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
